RACGP response – MSAC 1781 Risk assessment in prostate cancer using the Stockholm3 multiparametric blood test

Date: July 2024

The RACGP has provided feedback on MSAC application 1781 Risk assessment in prostate cancer using the Stockholm3 multiparametric blood test. 

The RACGP feedback on the use of Stockholm3 test for estimating the risk of having prostate cancer includes:

• noting there will be changes to current practice to collect additional requirements
• the need for education and resources
• financial and market implications
• inadequate use of evidence to support the benefits of Stockholm3

Read the submission

RACGP response – MSAC 1781 Risk assessment in prostate cancer using the Stockholm3 multiparametric blood test (PDF)